Related Experiment Video
Updated: May 20, 2026
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands
John R Hornick1, Dirk Spitzer, Peter Goedegebuure
1Department of Surgery, Harvard Medical School, Boston, MA, USA.
Abstract:
One major barrier in the development of pancreas cancer therapeutics is the selective delivery of the drugs to their cellular targets. We have previously developed several sigma-2 ligands and reported the discovery of a component of the receptor for these ligands. Several sigma-2 ligands have been shown to trigger apoptosis in pancreas cancer cells. More importantly, sigma-2 ligands are internalized rapidly by the cancer cells and are capable of delivering other small-molecule therapeutics. Here we review sigma-2 ligands and conjugates as a potential novel therapy suitable for investigation in patients with pancreatic cancer.
Insights
Targeted drug delivery for pancreatic cancer is challenging. Sigma-2 ligands offer a promising approach, selectively targeting cancer cells and delivering therapeutics for potential patient treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Selective drug delivery to pancreatic cancer cells remains a significant therapeutic hurdle.
- Sigma-2 ligands have demonstrated the ability to induce apoptosis in pancreatic cancer cells.
- These ligands are rapidly internalized by cancer cells, facilitating drug delivery.
Purpose of the Study:
- To review sigma-2 ligands and their conjugates as a potential therapeutic strategy for pancreatic cancer.
- To highlight the role of sigma-2 ligands in targeted drug delivery and cancer cell apoptosis.
Main Methods:
- Review of existing literature on sigma-2 ligands and their application in pancreatic cancer.
- Analysis of the mechanism of sigma-2 ligand internalization by cancer cells.
- Evaluation of the therapeutic potential of sigma-2 ligands and conjugates.
Main Results:
- Sigma-2 ligands can be selectively delivered to pancreatic cancer cells.
- These ligands trigger apoptosis in pancreatic cancer cells.
- Sigma-2 ligands serve as effective carriers for small-molecule therapeutics.
Conclusions:
- Sigma-2 ligands and their conjugates represent a novel and promising therapeutic avenue for pancreatic cancer.
- Their ability to target cancer cells and deliver drugs warrants further clinical investigation.
